TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1849730
Drug: Oral pyridostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pyridostigmine 30 mg 8 hourly
Study: 28760403
Drug: Immediate androgen-deprivation
Normalized name: hydrogen peroxide Topical Solution [IR DIP 10]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate androgen-deprivation therapy
Study: 28760403
Drug: Delayed androgen-deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed androgen-deprivation therapy
Study: 22282548
Drug: Palovarotene 5
Normalized name: palovarotene 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 5 mg·day(‐1) for 1 year
Study: 18385594
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous naloxone
Study: 26683986
Drug: Lactotripeptides (10.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides (10.2 mg/day)
Study: 11753137
Drug: Empiric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric treatment for interstitial cystitis; specific treatments not detailed.
Study: 1574973
Drug: Methohexitone infusion
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone infusion
Study: 3893488
Drug: Sotalol 1
Normalized name: sotalol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 1 mg/kg bolus intravenously plus 0.2 mg/kg intravenously over 12 hours
Study: 3893488
Drug: Digoxin 0.75
Normalized name: digoxin 0.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.75 mg intravenously, then disopyramide 2 mg/kg intravenous bolus and 0.4 mg/kg/h intravenously for 10 hours
Study: 11108307
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including placebo)
Study: 29031409
Drug: 15-20 mg
Normalized name: SALICYLIC ACID 15% 20MM PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-20 mg DSP (Group 1A)
Study: 29031409
Drug: 2.5-5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-5 mg DSP (Group 1B)
Study: 29031409
Drug: 15-20 mg
Normalized name: SALICYLIC ACID 15% 20MM PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-20 mg DSP (Group 2B)
Study: 23816952
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 9% CO2
Study: 23816952
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 0% CO2
Study: 20584994
Drug: Interaction effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interaction effect of genotype and CO2 dosage
Study: 18175148
Drug: IVMP (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP (intravenous methylprednisolone pulse), 30 mg/kg/day for 3 days
Study: 8200169
Drug: Cefoperazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone plus IVIG (500 mg/kg on days 1, 2, 3, and 8)
Study: 24750839
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment with dexamethasone 0.25‐0.3 mg/(kg·d) followed by oral prednisone tablets 0.5‐1 mg/(kg·d) for 7‐10 days
Study: 24750839
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with azithromycin and symptomatic therapies
Study: 20801122
Drug: Linaclotide 75
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linaclotide 75 μg
Study: 20801122
Drug: Linaclotide 150
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linaclotide 150 μg
Study: 20801122
Drug: Linaclotide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide (all doses)
Study: 31060836
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FOG) - 1.55 g of EPA + DHA per day for nine weeks
Study: 31060836
Drug: Placebo (PG)
Normalized name: PG-530742
DrugBank: PG-530742 (DB05495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PG) - Olive oil capsules
Study: 21030368
Drug: Formoterol (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (36 μg)
Study: 10195674
Drug: Pertussis vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertussis vaccine
Study: 2209411
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (8 mg) daily for 18 days, then daily or alternate days from day 19-36
Study: 31067546
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate supplementation to achieve serum HCO3- levels of 24 ± 1 mmol/L
Study: 23746749
Drug: Lower dentures
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dentures supported by implants
Study: 21193975
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine first
Study: 21193975
Drug: Hepatitis‐B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis‐B vaccine first
Study: 16840383
Drug: 0.5 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/d prednisone for 14 days
Study: 9375818
Drug: Pulse oral
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse oral calcitriol
Study: 7552095
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol
Study: 3908009
Drug: Co-trimoxazole (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (single-dose preoperative)
Study: 25133963
Drug: etoricoxib 30
Normalized name: Etoricoxib 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 30 mg (qd)
Study: 22394170
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of EPA-DHA (n = 453)
Study: 17344513
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/d for 14 days)
Study: 2183942
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg daily after RT)
Study: 7426142
Drug: Propranolol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.1 mg/kg intravenously followed by 320 mg in divided doses over 27 hours orally
Study: 10448260
Drug: Glycyl‐L‐glutamine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyl‐L‐glutamine supplementation
Study: 26070531
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy
Study: 18588736
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without therapy
Study: 21617973
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (Laser Smile™, Biolase®, San Clemente, USA) applied to the wound after surgery with 5 J/cm² energy density, 810 nm wavelength, and 0.5 W output power.
Study: 10084567
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isoflavones from red clover
Study: 10084567
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isoflavones from red clover
Study: 25466315
Drug: Humalog insulin
Normalized name: insulin lispro Cartridge [Humalog]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humalog insulin (Hlog)
Study: 30968588
Drug: Oral palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral palonosetron 0.50 mg
Study: 21034692
Drug: Levetiracetam (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (up to 2,500 mg/d flexibly dosed)
Study: 14979621
Drug: Doxazosin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin as add-on therapy
Study: 11337538
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg oral amphetamine
Study: 9398701
Drug: GH and
Normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH and LH‐releasing hormone (LHRH) analog
Study: 7956639
Drug: Nicotinamide (NCT)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (NCT) plus deflazacort (DFL) for 3 months (25 mg.kg-1.day-1 for NCT, 0.6 mg.kg-1.day-1 for DFL in the first month, 0.3 mg.kg-1.day-1 for DFL in the other 2 months)
Study: 3316240
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered at various intervals before tourniquet inflation
Study: 30784669
Drug: Low post-PCI
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low post-PCI bivalirudin infusion (0.25 mg/kg/h for ≤6 h)
Study: 30784669
Drug: No post-PCI
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No post-PCI bivalirudin infusion or heparin
Study: 25197733
Drug: Chocobar ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocobar ice cream without probiotics
Study: 15262457
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg
Study: 15262457
Drug: Dimenhydrinate 40
Normalized name: dimenhydrinate 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 40 mg
Study: 8483109
Drug: Zidovudine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 200 mg orally every 4 hours (1,200 mg daily)
Study: 27518195
Drug: 8-mg/h continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg/h continuous intravenous infusion of omeprazole (OME) for 72 hours
Study: 27518195
Drug: 40-mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg intravenous omeprazole (OME) bolus injection every 12 hours
Study: 2076713
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg daily)
Study: 20042452
Drug: Seawater gel
Normalized name: Sodium Chloride 2600 mg in 100 mL NASAL SPRAY [NasalAsalt All-Natural Seawater]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seawater gel nasal spray for 10 days
Study: 16415377
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin per day
Study: 16415377
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin per day
Study: 12868251
Drug: Daily exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exposure to a small, portable pulsing electromagnetic field generator
Study: 11825313
Drug: Anti-oxidant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidant therapy (specifics not provided)
Study: 7936855
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and phosphate therapy for 4.33 ± 2.19 years
Study: 21767407
Drug: etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg
Study: 30590861
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention based on the Theory of Triadic Influence (TTI) including a 50 min motivational interview and online self-help material, with follow-up support via email and group therapy.
Study: 28394521
Drug: Low dose-rate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose-rate brachytherapy using domestically manufactured I-125 seeds with a minimum therapeutic dose of 145 Gy, average of 57 seeds implanted (0.55 and 0.35 mCi per seed).
Study: 26835147
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg/day for first 6 months, then EC-MPS 720 mg/day until 12 months
Study: 20109120
Drug: Ultra absorbency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra absorbency tampon (15 g to 18 g)
Study: 20109120
Drug: Super-plus absorbency
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-plus absorbency tampon (12 g to 15 g)
Study: 7675951
Drug: Caffeine 150
Normalized name: caffeine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 150 mg
Study: 7529482
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime)
Study: 1706665
Drug: IVGG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVGG plus Aspirin (group G)
Study: 12529740
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (group A)
Study: 25649680
Drug: Once-daily risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily risperidone
Study: 25649680
Drug: Once-daily olanzapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily olanzapine
Study: 25649680
Drug: Twice-daily risperidone
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily risperidone
Study: 25649680
Drug: Twice-daily olanzapine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily olanzapine
Study: 23598785
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic (VSL3® Ferring), 2 tablets a day for 5 days, followed by 1 tablet daily for 10 days
Study: 23598785
Drug: Vaginal clindamycin
Normalized name: clindamycin Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal clindamycin 100 mg daily for 15 days
Study: 11374407
Drug: Steroid-free immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppression protocol
Study: 8299543
Drug: Nurse acting
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse acting as case manager working in conjunction with family doctors and community agencies to implement a treatment plan for depression.
Study: 8299543
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (recommended introduction).
Study: 3102407
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no drug therapy
Study: 23848141
Drug: Topical activated
Normalized name: collagen,activated Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical activated protein C (APC)
Study: 18279739
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg/day for 4 weeks
Study: 10678603
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy with neck-stretching exercises
Study: 10678603
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injections with neck-stretching exercises
Study: 28108429
Drug: Telerehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation treatment options with feedback and monitoring technology (FMT), video communication, and flexible exercise hours.
Study: 11417951
Drug: On-line HDF
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-line HDF once weekly
Study: 8277035
Drug: 0.1% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tretinoin cream
Study: 31868565
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin cream
Study: 2660996
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (200 IU per day)
Study: 27932067
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
Study: 12007948
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) brachytherapy
Study: 7955291
Drug: HeartMate 1000
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HeartMate 1000 IP LVAD with dipyridamole plus aspirin
Study: 7955291
Drug: HeartMate 1000
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HeartMate 1000 IP LVAD with miscellaneous agents
Study: 3042938
Drug: Enteric-coated microsphere
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated microsphere preparation (Pancrease)
Study: 18082664
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen for 7 days during the hormone-free interval
Study: 17349080
Drug: SYN treatment
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN treatment in cancer group
Study: 17349080
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received encapsulated maltodextrin and 10 g of maltodextrin
Study: 15058367
Drug: experimental toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental toothpaste formulation
Study: 26264399
Drug: Exenatide (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (twice daily)
Study: 15668637
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment
Study: 9715761
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micrograms twice daily for 4 weeks)
Study: 7873290
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate 1000 micrograms/day (500 micrograms twice daily) as the sole corticosteroid therapy
Study: 30125345
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with preoperative insulin resistance (IR)
Study: 30125345
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with normal insulin sensitivity (IS)
Study: 25761658
Drug: Functional beverage
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional beverage (FB) based on grape skin polyphenols, single-dose intake (187 mL)
Study: 23481448
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of trivalent inactivated influenza vaccine
Study: 23481448
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of trivalent inactivated influenza vaccine
Study: 9221486
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg human calcitonin (hCT)
Study: 1441864
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg rectally 12 h and 1 h before surgery and 20 mg 24 h postoperatively
Study: 3516580
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fenoverine 3-times daily for 20 days
Study: 8838779
Drug: Tacrine (Cognex)
Normalized name: tacrine Oral Capsule [Cognex]
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrine (Cognex) at a starting dose of 40 mg/day, increased by 40 mg/day every 6 weeks until target dose achieved.
Study: 30863852
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of oral 5FC and FLU
Study: 28992261
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of measles vaccine (MV) at 4.5 and 9 months of age
Study: 28992261
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of measles vaccine (MV) at 9 months of age
Study: 26576710
Drug: Tanezumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (200 μg/kg intravenous, 20 mg intravenous, 20 mg subcutaneous)
Study: 17943541
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronized 17beta-estradiol daily plus 10 mg dydrogesterone for 14 days of each 28-day cycle (n = 44)
Study: 17943541
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 36)
Study: 16230985
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (150 mg daily)
Study: 16230985
Drug: CoQ10 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (150 mg) plus vitamin E (1,000 IU daily)
Study: 9138278
Drug: IFN‐alpha‐2a 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐2a 3 MU three times weekly for 22 weeks
Study: 9138278
Drug: IFN‐alpha‐2a 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐2a 6 MU three times weekly for 22 weeks
Study: 2195426
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K1 administration
Study: 30357360
Drug: Thrice-weekly haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly haemodialysis (3×HD)
Study: 30357360
Drug: Twice-weekly haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly haemodialysis (2×HD)
Study: 17156291
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine
Study: 22634443
Drug: Vaccine recipients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine recipients
Study: 19858156
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition solution
Study: 19858156
Drug: Aluminum-depleted parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-depleted parenteral nutrition solutions